The proof-of-concept study also identified key metabolites that correlated with pulmonary fibrosis diagnosis and disease progression.
Doctors may be able to diagnose and measure the progression of pulmonary fibrosis by analyzing patients’ hair, according to early proof-of-concept research published in Lung.1 The researchers hope that in the long term, this discovery can help improve noninvasive and accurate detection of the fibrotic lung disease.
Fibrotic interstitial lung disease is often diagnosed late because its symptoms are vague, access to specialists is limited, and many doctors aren't familiar with it or know to look for it, delaying proper treatment. Though a biopsy is the most accurate test, it is rarely done because it is invasive. Typically, high-resolution CT scans are used for diagnosis, and regular lung function tests help monitor disease progression.
Woman running hand through hair | Image credit: Alessandro Grandini – stock.adobe.com
The researchers collected hair samples from 56 patients with pulmonary fibrosis and 14 patients without, then used advanced lab techniques to extract and analyze metabolites. They then used machine learning to create classification models, carefully fine-tuning these models with various validation and testing methods. This approach aimed to distinguish between patients with and without pulmonary fibrosis and to identify those with stable vs progressing disease.
The study achieved promising results in predicting whether patients had pulmonary fibrosis when measuring the area under the receiver operating characteristic (AUROC), with an AUROCTRAIN of 0.888 (0.794-0.982) and an AUROCTEST of 0.908. It also accurately predicted stable vs progressing disease, with an AUROCTRAIN of 0.833 (0.784-0.882) and an AUROCTEST of 0.799. For reference, an area under the curve (AUC) of 0.5 suggests no discrimination, while an AUC closer to 0 is poor, an AUC between 0.7 and 0.8 is acceptable, an AUC between 0.8 and 0.9 is excellent, and an AUC more than 0.9 is outstanding.2
The researchers also identified key metabolites for diagnosis, including:
Meanwhile, key metabolites associated with disease progression included:
“Hair is composed mainly of fibrous proteins, melanin, water, lipids, and minerals and provides a highly stable structure that retains endogenous metabolites for long term, providing a useful biological matrix in forensics analyses,” the researchers said. “Since hair has been shown to reflect the serum metabolome over time, it is unsurprising that some amino acids detected in this study are consistent with metabolites previously implicated in ILD [interstitial lung disease].”
The study's limitations include a small sample size and data from a single clinic. Although the findings suggest that hair metabolome analysis can predict pulmonary fibrosis and identify potential biomarkers, the approach mainly reveals correlations without establishing causation. Due to these limitations, the researchers noted that this study was exploratory and serves to generate hypotheses for future studies.
“The use of machine learning to predict the importance of biomarkers and their role in pulmonary fibrosis clinical outcomes is still a relatively unexplored field,” the researchers added. “This proof-of-concept study reveals a novel approach for detection of molecular signatures characteristic of pulmonary fibrosis.”
The researchers plan to carry out larger studies to confirm their findings. In the future, they hope that standardizing these new metabolite markers from hair samples could help diagnose and assess the risk of pulmonary fibrosis more quickly and accurately, leading to better, earlier, and more targeted treatments.
Reference
Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL
April 3rd 2025In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.
Read More
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More